Loading…
← CockpitCompetitor Analysis › INNV InnovAge Holding Corp.Open in the cockpit ↗

InnovAge Holding Corp.INNVCompetitor analysis, valuation and peers

United States · USD·Information Technology›Packaged Software

Runs PACE centers giving frail seniors all-inclusive medical, social and transportation care so they can stay home.

Momentum neutral 50
Mkt cap
$1.22B
US dollars, full cap
Free float
23%
of shares outstanding
$/day
$5.50M
20-day average traded
Fwd P/E
19.8×
forward earnings
ROIC−WACC
+19.0 pp
WACC 6.3%
Hurdle
-16 pp
Req g minus delivered
Next earnings
95 days
9 Feb 2027
Close · USD$8.97
1D-1.3%
1W-2.4%
1M-1.5%
3M-17.7%
6M+18.5%
YTD+72.8%
1Y+124.8%
ATR %5.2%
Beta0.64
52w lowhigh29.0% off high

What InnovAge does

Runs PACE centers giving frail seniors all-inclusive medical, social and transportation care so they can stay home.

Receives a fixed monthly payment per enrolled senior from Medicare and the state Medicaid programme, and must cover all that person's care out of it, so profit depends on keeping medical costs below the payment. Growth depends on enrolling more members and on regulators approving expansions; it listed in 2021.

Products and services

  • PACE day-center care
  • Primary/specialty clinical care
  • Transportation & social services

Customers

  • Medicare/Medicaid dual-eligible seniors

Where it sits in the supply chain

  • Senior care services
  • PACE (Program of All-Inclusive Care for…
  • Managed care + clinic operations

What could go right

  • Aging population/dual-eligible growth
  • New state/market expansion

What could go wrong

  • Regulatory/compliance scrutiny (past CMS issues)
  • Capitated cost overruns

Moat: narrow (regulatory licence, installed base). PACE is a capped, state-licensed model; incumbents hold scarce enrollment slots and centers.

Headquarters: Denver, Colorado, US · Employees: 2,500

Named competitors

  • ChenMed private or unlisted
  • CenterWell (Humana) HUM
  • WelbeHealth private or unlisted
  • Trinity Health PACE private or unlisted

InnovAge at a glance

Size InnovAge (INNV) is a United States Information Technology company (Packaged Software) with a market value of $1.22B, the 2128th largest of 3,117 United States companies the cockpit tracks. Shares closed at $8.97 on 6 Nov 2026.

Performance Over six months the shares gained 18.5%, against -3.7% for the median peer and -1.1% for the United States market (cap-weighted) — 8th highest of 19 in its peer set.

Growth Revenue grew 15.1% over the last twelve months (peer median +13.3%); the operating margin is 7.7% (peer median 6.6%).

Valuation It trades at 19.8× forward earnings against a peer median of 16.1× (6th most expensive of 14).

Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -16 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 19.0 points above its cost of capital (6.3% WACC).

Short interest Short interest is 0.8% of the free float (15 Oct 2026).

Next results Next results expected around 9 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012515011 May 202611 Aug 20266 Nov 2026INNV 122Peer median 94
Six months, rebased to 100: InnovAge against the median of its 20 peers (local-currency closes).

InnovAge financials

Reported figures in USD; fiscal year ends 2026-06-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
Revenue$1.02B$990M$854M$764M$688M
Revenue growth—+16%+12%+11%—
Gross profit$218M$207M$134M$113M$85.9M
EBITDA$99.9M$87.4M$26.6M$1.73M-$18.5M
Net income$9.00M-$2.54M-$30.3M-$21.3M-$40.7M
Free cash flow$76.3M$50.4M$26.6M-$44.8M-$3.12M
Capital expenditure$13.2M$14.3M$6.26M$7.91M$23.4M
Total debt$83.9M$87.0M$101M$113M$109M

Quarterly statements and history in the cockpit →

InnovAge competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-20%0%VIT-BMTG-ACYIENTPD2492600198301563APPS0354301382300766CRSR000676CHG300634BAND002605INNV6-month return →1-month return →
Up and to the right = strong over both horizons. InnovAge is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×100×200×300×VIT-BMTG-ACYIENTPD2492APPSCHG300634OPRA002605INNVRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. InnovAge is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%0%100%VIT-BMTG-ACYIENTAPPSCRSR000676CHGINNVGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. InnovAge is the large dot.

InnovAge competitors and peer comparison

Head to head with its named competitors (INNV vs HUM)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
InnovAge INNV$1.22B+18%+15%8%19.8×-6.7%
Humana HUM$52.1B+58%+18%2%32.9×15.2%

How InnovAge compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

InnovAge against its 20 peers (data as of 6 Nov 2026)
MeasureINNVPeer medianRank in peer set
1-month return-1.5%-6.4%8th highest of 21
6-month return+18.5%-3.7%8th highest of 19
Distance from 52-week high-29.0%-39.5%9th highest of 21
Revenue growth (TTM)+15.1%+13.3%10th highest of 21
Operating margin7.7%6.6%10th highest of 21
Forward P/E19.8×16.1×6th most expensive of 14
Growth the price implies (Req g, 7 yrs)-6.7%16.2%2nd least demanding of 15
Growth delivered (Del g)+9.2%+16.8%5th lowest of 15
Hurdle (Req g minus delivered)-15.9 pp+1.6 pp5th least demanding of 15
ROIC minus cost of capital+19.0 pp-6.1 pphighest of 21
EV / EBITDA11.8×12.9×4th cheapest of 11
Net debt / EBITDA-0.8×1.2×5th least indebted of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
InnovAge INNVUnited States$1.22B+18%+15%8%19.8×-6.7%+9.2%
Vitec Software VIT-B.STSweden$1.22B+18%+6%21%24.0×3.8%+22.6%
Modern Times Group MTG MTG-A.STSweden$1.22B+16%+42%11%6.6×-8.4%+23.7%
Cyient CYIENT.NSIndia$1.23B+24%+10%9%20.2×20.3%+12.0%
PagerDuty PDUnited States$1.23B+115%+2%7%11.1×12.8%+18.2%
Infomart 2492.TJapan$1.24B+70%+11%19%65.9×14.5%+16.5%
Datang Telecom Technology 600198.SSChina$1.25B-24%-11%-30%n/an/an/a
Beijing Zhongke WengeAI Science and Technology 1956.HKHong Kong$1.19Bn/a+28%-54%n/an/an/a
ICkey (Shanghai) Internet & Technology 301563.SZChina$1.19B-26%+26%4%n/an/an/a
Digital Turbine APPSUnited States$1.26B+200%+19%10%14.7×33.1%+12.5%
Chinasoft International 0354.HKHong Kong$1.18B0%+3%2%12.4×17.8%+3.1%
Fengzhushou 301382.SZChina$1.28B-32%+28%8%n/an/an/a
Merit Interactive 300766.SZChina$1.17B-30%+30%-2%n/an/an/a
Corsair Gaming CRSRUnited States$1.28B+63%+3%3%16.1×24.3%-2.9%
Shenzhen HQVT Technology 1392.HKHong Kong$1.28Bn/a+28%5%n/an/an/a
Genimous Technology 000676.SZChina$1.30B-7%+3%6%n/a14.1%-17.5%
CHAPTERS CHG.DEGermany$1.30B+48%+63%-21%294.5×43.9%+178.6%
Richinfo Technology 300634.SZChina$1.30B-15%-11%10%31.2×20.8%+19.9%
Bandwidth BANDUnited States$1.31B-19%+15%-1%19.6×19.3%+17.0%
Opera Limited Sponsored ADR OPRAUnited States$1.31B-21%+23%16%11.9×4.5%+30.1%
Shanghai Yaoji Technology 002605.SZChina$1.14B-11%-3%20%15.0×6.4%+1.0%

Questions

Who are InnovAge's main competitors?
Named competitors: ChenMed (private or unlisted), CenterWell (Humana) (HUM), WelbeHealth (private or unlisted), Trinity Health PACE (private or unlisted). The cockpit's measured peer set (industry) also includes Vitec Software (VIT-B.ST), Modern Times Group MTG (MTG-A.ST), Cyient (CYIENT.NS), PagerDuty (PD), Infomart (2492.T), Datang Telecom Technology (600198.SS).
Is InnovAge expensive compared with its peers?
On forward p/e it trades at 19.8× against a peer median of 16.1×, 6th most expensive of 14 in its peer set. For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -16 pp: the price already allows for a slowdown.
How has InnovAge stock performed?
Over six months to 6 Nov 2026 the shares returned +18.5% against -3.7% for the median peer; over one year +124.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.